Blood Testing Market Size & Share 2026-2035

Blood Testing Market Size

The global blood testing market was valued at USD 89.5 billion in 2025 and is projected to grow from USD 94.8 billion in 2026 to USD 179.8 billion by 2035, expanding at a CAGR of 7.4%, according to the latest report published by Global Market Insights Inc. This steady growth is driven by growing burden of, chronic and infectious diseases, technological advancements in blood testing devices and burgeoning number of point-of-care (POC) testing centers.

The market increased from USD 80.3 billion in 2023 to USD 84.7 billion in 2024. The rising prevalence of chronic diseases is a major driver for the blood testing market, as conditions such as cardiovascular disorders, cancer, diabetes, and chronic respiratory illnesses require regular diagnostic monitoring and early detection to manage treatment effectively. This growing need for accurate and timely blood analysis is fueling demand for advanced testing technologies and consumables.
 

For example, according to the World Health Organization (WHO), noncommunicable diseases (NCDs caused at least 43 million deaths globally in 2021, accounting for 75% of non-pandemic-related mortality, with 18 million occurring before age 70 and 82% of these premature deaths concentrated in low- and middle-income countries (LMICs). Overall, 73% of all NCD deaths are in LMICs, where healthcare systems are rapidly expanding to improve diagnostic capabilities. This trend is driving hospitals, diagnostic laboratories, and point-of-care facilities to invest in modern blood testing solutions along with consumables like reagents, test kits. These products ensure accurate results, faster turnaround times, and compliance with stringent regulatory standards while supporting high-volume testing environments. In conclusion, the escalating global burden of chronic diseases, particularly in emerging economies, is significantly boosting demand for advanced blood testing technologies and consumables.
 

Additionally, rising global healthcare spending and supportive government initiatives are significantly boosting the blood testing market. Higher healthcare budgets enable hospitals, diagnostic centers, and laboratories to invest in advanced testing technologies, automation systems, and high-quality consumables, improving diagnostic accuracy and efficiency. Governments and health organizations are introducing favorable reimbursement policies, expanding insurance coverage, and funding preventive care programs, which encourage routine blood testing for early disease detection and management.
 

In emerging economies, public-private partnerships and infrastructure development are accelerating the adoption of modern diagnostic solutions. Additionally, initiatives promoting universal health coverage and screening programs for chronic and infectious diseases are driving demand for blood tests across diverse patient populations. These factors collectively create a strong foundation for market growth by improving accessibility, affordability, and adoption of advanced blood testing technologies worldwide.
 

A blood test is a common medical check-up where a small blood sample is analyzed in a lab to check your overall health, diagnose diseases, monitor conditions like diabetes, see how organs (liver, kidneys, heart, thyroid) are working, and find out if treatments are effective by measuring cells, chemicals, proteins, and other substances. Usually taken from a vein in the arm with a needle or a finger prick, these tests provide vital clues about your body's internal state, from fighting infections to checking organ function.

Blood Testing Market Trends

• The blood testing industry is witnessing rapid technological progress, driven by innovations in automation, miniaturization, and digital integration. Modern devices now feature high-throughput analyzers, point-of-care (POC) testing platforms, and advanced molecular diagnostic systems that deliver faster, more accurate results.
   
• Emerging technologies such as microfluidics, lab-on-a-chip, and AI-powered diagnostic algorithms are transforming traditional laboratory workflows into highly efficient, automated processes. These advancements enable comprehensive testing for multiple parameters from a single sample, reducing turnaround time and improving patient outcomes.
   
• Technological improvements significantly enhance efficiency, accuracy, and accessibility, which are critical for meeting the growing demand for diagnostic services. Automated systems reduce manual errors and labor costs, while POC devices allow testing in decentralized settings such as clinics and homes, expanding market reach. Integration with digital health platforms and cloud-based data management supports telemedicine and remote monitoring, creating new revenue streams for manufacturers and service providers. These innovations also align with global trends toward preventive healthcare and personalized medicine, further driving adoption.
   
• Leading companies are investing heavily in next-generation blood testing technologies. For instance, Abbott has developed advanced point-of-care devices like the i-STAT system, which provides rapid, accurate blood chemistry and hematology results at the patient’s bedside. Such innovations cater to the growing need for quick diagnostics in emergency care and resource-limited settings, demonstrating how technological leadership translates into market expansion.
   
• As a result, technological advancements in blood testing devices are reshaping the diagnostic landscape by improving speed, accuracy, and convenience. These innovations not only meet the rising demand for chronic disease monitoring and preventive care but also open new opportunities in home-based testing and digital health integration.
   

Blood Testing Market Analysis

Based on test type, the blood testing market is segmented into complete blood count test, blood glucose test, heart test, infectious disease screening, kidney test- renal profile, cholesterol test- lipid profile test, cancer test, urine test antibodies test rheumatoid factor and other test type. The complete blood count segment was valued at USD 13.2 billion in 2025 and held a significant market share of 14.7%.
 

• A Complete Blood Count (CBC) is one of the most fundamental diagnostic tests, providing critical insights into a patient’s overall health by measuring parameters such as red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. This test is essential for detecting conditions like anemia, infections, immune system disorders, and hematologic diseases. Its versatility and routine use in preventive care, pre-surgical evaluations, and chronic disease monitoring make CBC useful in diagnostic testing.
   
• The dominance of CBC in the blood testing market is attributed to its high demand across hospitals, diagnostic laboratories, and point-of-care settings. As healthcare systems emphasize early detection and continuous monitoring, CBC remains indispensable due to its cost-effectiveness and comprehensive diagnostic value. The growing prevalence of lifestyle-related disorders and infectious diseases further accelerates the need for routine CBC testing.
   
• Cancer diagnosis and treatment heavily rely on blood testing, including CBC, to monitor patient health and treatment response. For instance, in 2022, there were an estimated 536,245 people living with leukemia in the U.S., a condition that requires frequent CBC tests for disease progression and therapy management. This high incidence of blood-related cancers underscores the critical role of CBC in oncology, creating demand for advanced blood testing solutions.
   

Based on product, the blood testing market is segmented into reagents and kits, instruments and software. The reagents and kits segment was valued at USD 52.7 billion in 2025 and held a significant market share of 58.8%.
 

• Reagents and kits are essential components in blood testing, comprising chemical substances, buffers, and ready-to-use test kits that enable accurate analysis of blood samples. These products are used across various testing platforms, including hematology, immunoassay, molecular diagnostics, and clinical chemistry. They ensure precision in detecting biomarkers, pathogens, and disease indicators, making them indispensable for routine and specialized blood tests.
   
• Reagents and kits play a critical role in the blood testing market due to their recurring demand and importance in every diagnostic procedure. Unlike instruments, which are one-time investments, reagents and kits require continuous replenishment, creating a steady revenue stream for manufacturers. The growing prevalence of chronic and infectious diseases, coupled with the expansion of point-of-care testing and home-based diagnostics, further accelerates consumption. Additionally, advancements in reagent formulations for faster processing and higher sensitivity enhance testing efficiency, supporting market growth.
   
• For instance, Roche Diagnostics offers the Elecsys reagent kits, widely used for immunoassay-based blood testing. These kits deliver high accuracy and reliability, meeting the increasing demand for advanced diagnostic solutions in hospitals and laboratories worldwide.
   
• As a result, reagents and kits serve are important part of the blood testing market, driving consistent revenue and enabling accurate diagnostics across diverse applications. Their indispensable role in routine and specialized testing, combined with technological improvements and rising global healthcare needs, ensures that this category will continue to be a key growth driver.
   

Based on method, the market is segmented into automated and manual. The automated segment was valued at USD 63.8 billion in 2025
 

• Automated blood testing methods involve the use of advanced instruments and integrated systems to perform diagnostic tests with minimal human intervention. These systems utilize robotics, software algorithms, and high-throughput analyzers to process large volumes of samples quickly and accurately. Automation covers a wide range of applications, including hematology, clinical chemistry, immunoassays, and molecular diagnostics, ensuring consistent results and reducing manual errors.
   
• Additionally, automation is transforming the blood testing market by improving efficiency, scalability, and turnaround times. Laboratories and hospitals increasingly adopt automated systems to handle growing test volumes driven by chronic disease prevalence and preventive health programs. Automated platforms reduce labor costs, optimize workflow, and enable real-time data integration with electronic health records, supporting personalized medicine and telehealth initiatives.
   
• For instance, Siemens Healthineers offers the ADVIA hematology systems, which deliver fully automated blood analysis with high precision and speed. Such solutions cater to large diagnostic centers and hospitals, meeting the demand for rapid and reliable testing in high-volume environments.
   
• These benefits make automation a strategic investment for healthcare providers, fueling market expansion.
   

Based on end use, the blood testing market is bifurcated into hospitals, diagnostic centers, pathology labs, blood banks and end users. The hospitals segment held a significant market share of 47.2% in 2025.
 

• Hospitals remain the primary point of care for patients requiring blood tests, as they offer comprehensive diagnostic capabilities and access to advanced laboratory infrastructure. These facilities are equipped with automated hematology analyzers, clinical chemistry systems, and immunoassay platforms, enabling accurate and timely testing for a wide range of conditions, including chronic diseases, infections, and pre-surgical evaluations. Their ability to provide complete diagnostic services, including sample collection, analysis, and follow-up consultations, makes hospitals the most preferred setting for blood testing.
   
• The dominance of hospitals in this segment is by the availability of skilled laboratory technicians, pathologists, and integrated diagnostic units. Hospitals also serve as hubs for preventive health programs and early detection initiatives, ensuring timely diagnosis and reducing complications associated with late-stage diseases. The presence of advanced testing infrastructure and trained personnel enhances accuracy and patient confidence, driving the adoption of blood testing solutions in these settings.
   
• Growing integration of automation and digital platforms within hospital laboratories is further improving efficiency and accessibility. Hospitals are increasingly adopting AI-powered hematology systems and cloud-based data management solutions that enable automated result interpretation, risk assessment, and standardized reporting.
   

As the global burden of chronic and infectious diseases continues to rise, hospitals will play a pivotal role in blood testing and diagnostics. Investments in advanced laboratory technologies, telehealth infrastructure, and integrated care models will strengthen their position as the leading end-user segment. With growing emphasis on automation and digital connectivity, hospitals are set to remain central to the expansion of the market.
 

North America Blood Testing Market

The North America region accounted for 32% of the global blood testing market in 2025. The market in North America is experiencing robust expansion, driven by the region’s advanced healthcare infrastructure and technological advancements.
 

• The U.S. blood testing industry was valued at USD 22.1 billion and USD 23.1 billion in 2022 and 2023, respectively. The market size reached USD 25.3 billion in 2025, growing from USD 24.1 billion in 2024.
   
• The rising prevalence of chronic diseases in the U.S. is a major factor fueling the demand for blood testing. Conditions such as cancer, cardiovascular disorders, diabetes, and genetic blood disorders require frequent diagnostic monitoring to ensure timely treatment and disease management. Blood tests are essential for early detection, therapy planning, and ongoing evaluation, making them a cornerstone of modern healthcare.
   
• For instance, according to the American Red Cross, millions of diagnostic tests are performed annually to monitor chronic conditions and detect complications early. Sickle cell disease alone affects approximately 90,000 to 100,000 people in the U.S., with about 1,000 babies born with the condition each year. These patients require regular blood testing for hemoglobin levels, organ function, and treatment response, creating a continuous need for advanced diagnostic solutions.
   
• To meet this growing demand, healthcare facilities are investing in high-performance blood testing technologies. Automated hematology analyzers, immunoassay systems, and molecular diagnostic platforms are being widely adopted to improve accuracy and efficiency.
   
• As chronic diseases continue to rise, U.S. healthcare facilities are investing heavily in high-performance blood testing to ensure safety, compliance, and efficiency stimulating the market growth.
   

Europe Blood Testing Market

Europe blood testing industry accounted for USD 23.9 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• The European blood testing market is experiencing significant growth due to rapid technological innovations in diagnostic devices. Advanced automation, high-throughput analyzers, and integrated digital platforms are transforming traditional laboratory workflows into efficient, error-free processes. Technologies such as microfluidics, lab-on-a-chip systems, and AI-powered diagnostic algorithms are enabling faster, more accurate results while reducing manual intervention. These advancements support comprehensive testing for multiple parameters from a single sample, improving patient care and operational efficiency.
   
• Additionally, technological progress is driving adoption across hospitals, diagnostic laboratories, and point-of-care settings in Europe. Automated systems reduce turnaround times, optimize resource utilization, and enhance compliance with stringent EU regulations.
• As healthcare systems prioritize early detection and personalized care, investments in automation, AI-driven platforms, and digital integration will continue to accelerate market growth.
   

Germany's blood testing market is projected to experience steady growth between 2026 and 2035.
 

• The German blood testing industry is experiencing steady growth, largely driven by the rising prevalence of chronic and infectious diseases across the country. As public health challenges such as diabetes, cardiovascular disorders, and emerging infections persist, the demand for accurate and timely blood diagnostics has intensified.
   
• For instance, the European Centre for Disease Prevention and Control (ECDC) reported thousands of cases of blood-borne infections in Germany in 2022, including hepatitis and HIV, underscoring the need for accessible and efficient blood testing solutions. Advanced blood testing technologies help address these challenges by enabling early detection, improving treatment outcomes, and supporting preventive healthcare strategies.
   
• As the burden of chronic and infectious diseases in Germany continues to rise, so does the demand for innovative and reliable blood testing solutions.
   

Asia Pacific Blood Testing Market

The Asia Pacific region is projected to show a lucrative growth of about 8.8% during the forecast period.
 

• The Asia-Pacific blood testing industry is experiencing strong growth, primarily driven by the rising prevalence of chronic and infectious diseases such as diabetes, cardiovascular disorders, hepatitis, and HIV. These health challenges have significantly increased the demand for accurate and accessible blood testing solutions that support early diagnosis and effective treatment.
   
• For instance, according to the International Diabetes Federation, in the Western Pacific region, the number of adults aged 20–79 years with diabetes surged from 44.1 million in 2000 to 131.9 million in 2011, and further to 215.4 million in 2024. Projections estimate this number will reach 253.8 million by 2050, underscoring the urgent need for advanced blood testing technologies.
   
• As the burden of chronic and infectious diseases continues to rise across Asia-Pacific, the demand for innovative and reliable blood testing solutions is expected to accelerate significantly.
   

Japan blood testing market is poised to witness lucrative growth between 2026 and 2035.
 

• The Japan blood testing industry has grown due to technological advancements in blood testing devices. Innovations in automated analyzers, molecular diagnostic platforms, and portable blood testing systems are transforming traditional diagnostic practices by enabling faster, more accurate, and decentralized testing.
   
• These technologies support real-time monitoring and personalized diagnostics, allowing healthcare providers to make immediate decisions during patient consultations. This is particularly valuable in managing chronic conditions such as diabetes and cardiovascular diseases, as well as detecting blood-borne infections, where timely intervention can significantly improve outcomes.
   
• Japan’s strong focus on healthcare innovation is contributing to the increased adoption of advanced blood testing devices across hospitals, clinics, and home care settings.
   

Latin America Blood Testing Market

Brazil is experiencing significant growth in the blood testing industry. 
 

• The blood testing industry in Brazil is witnessing significant growth, driven by technological advancements in blood testing devices, rising prevalence of chronic diseases like diabetes and cardiovascular conditions, and the need for timely clinical decisions are contributing to the expansion of blood testing adoption across the country. These solutions enable early detection and treatment initiation, especially in remote and underserved areas, thereby improving patient outcomes.
   
• Healthcare providers across Brazil are increasingly integrating advanced blood testing technologies into their clinical workflows to enhance diagnostic efficiency, reduce the burden on centralized laboratories, and support preventive care strategies.
   
• For instance, according to the International Diabetes Federation (IDF), Brazil had over 16.6 million adults living with diabetes in 2024, representing a 10.6% prevalence among its 155 million adult population. Brazil is part of the IDF South and Central America (SACA) region, which currently has 35 million people with diabetes, projected to rise to 52 million by 2050. This surge in diabetes cases creates a strong need for blood testing devices such as glucose analyzers, HbA1c testing systems. The growing diabetic population is placing pressure on the healthcare system, accelerating the need for accessible, accurate, and cost-effective blood testing solutions.
   

Middle East and Africa Blood Testing Market

• Major drivers of the Saudi Arabia blood testing industry is technological advancements in blood testing devices. Innovations such as automated analyzers, molecular diagnostic platforms, and portable blood testing systems are revolutionizing diagnostic practices by enabling faster, more accurate, and decentralized testing.
   
• Saudi Arabia’s strong focus on modernizing its healthcare infrastructure, coupled with the integration of digital health tools and connectivity solutions, further accelerates the adoption of advanced blood testing technologies across hospitals, clinics, and home care settings. This technological progress is expected to significantly enhance diagnostic accuracy and accessibility, making it a key growth driver for the market.
   

Blood Testing Market Share

• The leading companies in the egg freezing and embryo banking market include F. Hoffmann-La Roche, Abbott Laboratories, Siemens Healthineers, Danaher, and Thermo Fisher Scientific, collectively accounting for a 60% market share of the global market.
   
• Leading companies in the blood testing market are driving innovation to enhance sample collection, analysis, and reporting worldwide. They are investing in advanced automated analyzers, high-throughput molecular testing platforms, and AI-powered diagnostic tools to ensure accuracy, speed, and efficiency. These technological advancements improve diagnostic precision, reduce turnaround times, and support early disease detection, ultimately improving patient outcomes and lowering operational costs for healthcare providers.
   
• Through acquisitions and global expansion strategies, these companies are strengthening their position in the blood testing ecosystem. Partnerships with hospitals, diagnostic laboratories, and healthcare networks are enabling broader access to advanced blood testing solutions, particularly in emerging markets. This collaborative approach ensures better diagnostic coverage, timely availability of test results, and improved continuity of care for chronic and critical conditions.
   
• In conclusion, the focus on automation, digital integration, and regulatory compliance by these industry leaders will significantly shape the future of the market. Integration of IoT-enabled devices and AI-driven predictive analytics will further enhance operational efficiency, accuracy, and safety standards.
   
• Their commitment to innovation and strategic alliances will accelerate adoption globally, improve patient outcomes, and drive sustained market growth. As healthcare systems prioritize modernization and preventive care, these advancements will remain central to meeting the rising demand for reliable and cost-effective blood testing solutions.
   

Blood Testing Market Companies

Few of the prominent players operating in the blood testing industry include:

• Danaher
• F Hoffmann-La Roche Ltd
• Abbott Laboratories
• BioMerieux SA
• Grifols
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc
• Siemens Healthineers
• Sinocare Inc
• Trinity Biotech
• Thermo Fisher Scientific Inc
• B. Braun Melsungen AG
   
• Thermo Fisher Scientific

Thermo Fisher Scientific leverages its expertise in life sciences to deliver innovative blood testing solutions, including reagents, molecular diagnostic platforms, and laboratory automation systems. The company emphasizes precision, compliance, and data-driven insights through advanced software integration. Strategic partnerships and acquisitions strengthen Thermo Fisher’s position in personalized medicine and genetic testing, enabling early detection and improved patient care. Its commitment to sustainability and digital transformation ensures continued growth in the blood testing market.
 

• Danaher

Danaher, through Beckman Coulter and Radiometer, provides cutting-edge blood testing technologies that combine automation with advanced analytics. Beckman Coulter specializes in high-throughput laboratory systems, while Radiometer focuses on critical care blood gas analysis. The company invests heavily in R&D and connectivity solutions to streamline diagnostic workflows and reduce turnaround times. Danaher’s strategic acquisitions and global reach reinforce its leadership in delivering reliable and efficient blood testing solutions.
 

• BioMerieux SA

bioMérieux is a global leader in in-vitro diagnostics with a strong presence in the blood testing market. The company focuses on advancing diagnostic accuracy through automation, digital integration, and data-driven solutions. Its strategy emphasizes innovation in microbiology and molecular diagnostics, supporting faster and more reliable results for critical conditions. Through strategic partnerships and global expansion, bioMérieux continues to strengthen its role in improving healthcare outcomes and addressing the growing demand for efficient blood testing solutions worldwide.
 

Blood Testing Industry News

• In November 2025 Abbott Acquired Exact Sciences for $21 Billion. This strategic move positions Abbott as a leader in the fast-growing cancer diagnostics segment. The acquisition expands Abbott’s portfolio with Exact Sciences’ innovative products, including Cologuard for colorectal cancer screening, Oncotype DX® for breast cancer treatment decisions, Oncodetect for molecular residual disease detection, and Cancerguard, a multi-cancer early detection blood test. Together, the companies aimed to accelerate innovation, broaden access to life-saving diagnostics, and improve early cancer detection globally.
   

The blood testing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Complete blood count test
• Blood glucose test
• Heart test
• Infectious disease screening
• Kidney test- renal profile
• Cholesterol test- lipid profile test
• Cancer test
• Urine test
• Antibodies test – rheumatoid factor
• Other test types

Market, By Product

• Reagents and kits
• Instruments
• Software

Market, By Method

• Automated
• Manual

Market, By End Use

• Hospitals
• Pathology labs
• Blood banks
• Diagnostic centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE